

PHARMION CORP  
Form 8-K  
September 22, 2004

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported)

**September 22, 2004**

---

**Pharmion Corporation**

(Exact name of registrant as specified in its charter)

---

**Delaware**

---

**000-50447**

---

**84-1521333**

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

---

2525 28th Street, Boulder, Colorado

---

80301

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

720-564-9100

---

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: PHARMION CORP - Form 8-K

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 2.02. Disclosure of Results of Operations and Financial Condition**

On September 21, 2004, the Pharmion Corporation issued a press release announcing the EMEA acceptance of the Company's Marketing Authorization Application for Vidaza. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits**

(c) Exhibit 99.1 Press Release dated September 21, 2004.

This exhibit is furnished pursuant to Item 9.01 and shall not be deemed to be filed.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMION CORPORATION

Date: 9-22-04

By: **/s/ Erle T. Mast**  
Erle T. Mast  
Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated September 21, 2004 announcing EMEA acceptance of the Company's Marketing Authorization Application for Vidaza.